Physician profile
Anthony G Sauerwein
NPI 1750340857
$10,108.04
in general payments reported to CMS, 2019-2025
26 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,255 · 2020: $3,082 · 2021: $646 · 2022: $773 · 2023: $1,432 · 2024: $1,017 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,352.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $2,118.93 | 2020-2021 | |
| Boston Scientific Corporation | $2,038.01 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Amgen INC. | $920.44 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $881.82 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $721.31 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $668.27 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $550.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $523.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.07 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $259.71 | 2019-2024 | Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $240.20 | 2019-2025 | Lifevest |
| Amarin Pharma, INC. | $145.64 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $139.76 | 2022-2024 | Optimizer, Optimizer |
| Philips North America LLC | $119.76 | 2022-2024 | (5044) Mcot |
| Merck Sharp & Dohme LLC | $93.18 | 2023-2025 | Verquvo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $92.79 | 2023 | |
| Kestra Medical Technology Services, INC. | $75.04 | 2023-2025 | Assure Wcd |
| Kowa Pharmaceuticals America, INC. | $35.74 | 2019-2020 | |
| Abbott Laboratories | $30.68 | 2024 | Cardiomems |
| Abiomed | $24.94 | 2025 | |
| Edwards Lifesciences Corporation | $23.61 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $20.38 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2025 | |
| Cardiva Medical, INC. | $16.86 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $16.38 | 2024 | Opsumit, Uptravi |
| W. L. Gore & Associates, INC. | $16.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Sauerwein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.